Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 13 Oct, 20:13 UTC

Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The growing field of companies pursuing ALK7 includes GSK and Arrowhead Pharmaceuticals. The post Roche Puts Up $100M to Pursue…

science

Sources

• T2Roche Puts Up $100M to Pursue Promising But Competitive New Target in ObesityFierce Biotech / Fierce Healthcare / MedCity / GEN13 Oct, 20:13